Establish the largest possible real-life cohort collecting long-term follow-up of a maximum number of CML patients in order to carry out observational studies: epidemiological, identification of subgroups according to their response to treatment, evaluation of new molecules in real life, therapeutic discontinuations, impact of the evolution of recommendations, etc.
Observational study collecting real-life clinico-biological data from patients with CML. Data are collected prospectively and retrospectively, from diagnosis and throughout the long-term follow-up of CML (follow up continues after treatment stopped).
Study Type
OBSERVATIONAL
Enrollment
3,500
CH Annecy Genevois
Annecy, France
RECRUITINGUniversity Hospital, Caen
Caen, France
RECRUITINGClinical and biological data collection
Aims of the registry are the collection of clinical data to gain further insights about patients's CML treated with ITK's (treatment, prognosis, therapeutical response).
Time frame: Until death or last follow up (up to 30 years)
Prognosis score for CML (Sokal, ELTS, Eutos, Hasford)
Time frame: At diagnosis
BMI with evaluation of weight and height
Time frame: Until death or last follow up (up to 30 years)
Evaluation of major molecular response (MMR) with transcript BCR::ABL in %
Time frame: Until death or last follow up (up to 30 years)
Evaluation of molecular response MR4 with transcript BCR::ABL in %
Time frame: Until death or last follow up (up to 30 years)
Evaluation of molecular response MR4.5 with transcript BCR::ABL in %
Time frame: Until death or last follow up (up to 30 years)
Evaluation of molecular response MR5 with transcript BCR::ABL in %
Time frame: Until death or last follow up (up to 30 years)
Evaluation of cytogenetic response
Time frame: Until death or last follow up (up to 30 years)
Evaluation of TKI efficacy based on transcript BCR::ABL in %
Time frame: Until death or last follow up (up to 30 years)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
CHU Clemront-Ferrand
Clermont-Ferrand, France
RECRUITINGCentre Hospitalier Emile Roux
Le Puy-en-Velay, France
RECRUITINGUniversity Hospital, Limoges
Limoges, France
RECRUITINGInstitut Paoli-Calmettes
Marseille, France
RECRUITINGCentre Hospital, Nancy
Nancy, France
RECRUITINGBicetre Hospital
Paris, France
RECRUITINGHopital Paul Brousse
Paris, France
RECRUITINGRennes University Hospital
Rennes, France
RECRUITING...and 4 more locations
Evaluation of TKI tolerance (adverses events)
Time frame: Until death or last follow up (up to 30 years)
Calcul in month of the duration of maintenance TFR (treatment free remission) after stop TKI for thérapeutic response
Time frame: Until death or last follow up (up to 30 years)
Listing of major medical history of patient's CML
Time frame: Until death or last follow up (up to 30 years)